← Back to Search

Other

Rapid Testing for Bacterial Blood Infections

N/A
Recruiting
Led By Matthew Semler, MD, MSc
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinician has ordered intravenous vancomycin
Age ≥ 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 14 days
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the use of a rapid diagnostic test called the T2Bacteria® Panel with the standard method of using blood cultures to identify bacterial infections in patients who are suspected to have an infection

Who is the study for?
Adults over 18 who are in the Emergency Department at Vanderbilt University Hospital, have been given intravenous vancomycin, and had blood cultures ordered within 12 hours of arriving. The trial is for those suspected to have a bacterial bloodstream infection.
What is being tested?
The study compares the T2Bacteria Panel, which tests directly from blood for bacteria, with usual care using blood cultures that take longer to show results. It aims to see if this rapid test can improve antibiotic use and patient outcomes.
What are the potential side effects?
While not explicitly stated here, potential side effects may relate to unnecessary exposure to broad-spectrum antibiotics like vancomycin such as kidney damage or hearing issues due to toxicity and increased risk of antimicrobial resistance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My doctor has prescribed IV vancomycin for me.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time to last dose of intravenous vancomycin
Secondary study objectives
Time to last dose of systemic anti-pseudomonal beta-lactam antibiotic

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Usual CareActive Control1 Intervention
Patients will receive blood cultures and will not receive direct-from-blood testing.
Group II: Direct-from-blood testingActive Control1 Intervention
In addition to usual care, patients will receive direct-from-blood testing using the T2Bacteria® Panel.

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
900 Previous Clinical Trials
939,006 Total Patients Enrolled
Matthew Semler, MD, MScPrincipal InvestigatorVanderbilt University Medical Center
~273 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top